Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Shuttle Pharmaceuticals, Inc.”

9 pharma patents match "Shuttle Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 9
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 9 pharmaceutical patents matching "Shuttle Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

9 results for “Shuttle Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12357650

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12077515

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  3. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  4. US 11584733

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  5. US 11407723

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  6. US 11034667

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  7. US 10745352

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Shuttle Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  8. US 10730834

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Shuttle Pharmaceuticals, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  9. US 9809539

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Shuttle Pharmaceuticals, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted